News|Articles|August 24, 2026

Pharmaceutical Technology

  • A Recap of CPHI Milan 2026 eBook
  • Volume 50

From Detection to Prediction: Modern Analytical Approaches for Nitrosamine Risk

Fact checked by: Ronald Panarotti

Nitrosamine control is about understanding why nitrosamines form, where they may form, and how to prevent their formation.

Nitrosamines have been known carcinogens for decades, but their emergence in pharmaceutical products in 2018 transformed them into a central regulatory and analytical priority.1 What began as a targeted investigation into a handful of small nitrosamines has since expanded into a complex, mechanism-driven discipline requiring predictive assessment, structural evaluation, and highly sensitive analytical methods.

Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.